PNT001 is a monoclonal antibody immunotherapy developed by Pinteon Therapeutics targeting a specific pathological form of tau protein known as cis-phosphorylated tau at threonine 231 (cis-pT231)[1]. This antibody represents a novel approach in tau immunotherapy by specifically targeting the cis conformation of phosphorylated tau, which is resistant to dephosphorylation and degradation, and has been implicated in the pathogenesis of Alzheimer's disease, traumatic brain injury, and potentially Chronic Traumatic Encephalopathy (CTE)[2].
Unlike conventional anti-tau antibodies that target various phosphorylated epitopes or total tau, PNT001's unique specificity for the cis-pT231 isoform represents a mechanistic distinction that may offer enhanced pathological relevance. The cis conformation of pT231 tau has been shown to be more toxic and aggregation-prone than the trans (normal) phosphorylated form.
The therapeutic target of PNT001 is the cis isomer of tau phosphorylated at threonine 231 (cis-pT231)[2:1]. This specific post-translational modification is pathologically significant because:
PNT001 binds specifically to:
The mechanism by which PNT001 may exert therapeutic effects includes[3]:
The cis-pT231 tau isoform was identified as a pathological driver in tauopathies through extensive research demonstrating[4]:
The cis-pT231 isoform is detected in:
| Parameter | Details |
|---|---|
| Sponsor | Pinteon Therapeutics |
| Start Date | September 2019 |
| Design | Single ascending dose, placebo-controlled |
| Participants | 49 healthy adult volunteers |
| Dose Range | 33 mg to 4,000 mg |
| Route | Intravenous infusion |
| Duration | 12-week follow-up |
The Phase 1 trial demonstrated[5]:
| Parameter | Details |
|---|---|
| Start Date | March 2021 |
| Design | Multiple ascending dose in acute TBI |
| Participants | Planned 64, enrolled 1 |
| Status | Terminated for non-safety reasons |
| Duration | 12-week monitoring |
The TBI study was terminated for business reasons, not safety concerns. The data collected showed antibody reached target concentrations in the single enrolled patient.
PNT001's development for Alzheimer's disease and traumatic brain injury is currently inactive, though the scientific foundation for cis-pT231 targeting remains strong and may inform future development programs.
| Feature | PNT001 | Other Anti-Tau Antibodies |
|---|---|---|
| Target | cis-pT231 | Various (total tau, p-tau S396/404, N-terminal) |
| Specificity | Conformation-specific | Epitope-specific |
| Pathological relevance | Early, toxic isoform | Broader tau pool |
| Development status | Inactive | Various stages |
The targeting of cis-pT231 provides potential advantages[6]:
The development for TBI reflects the important link between acute brain injury and chronic neurodegeneration[7]:
Studies supporting PNT001 development included:
The inactivation of PNT001 development reflects broader challenges in tau immunotherapy:
The cis-pT231 target remains scientifically compelling:
cis-Phosphorylated tau: A pathological isoform in Alzheimer disease. Nature Neuroscience, 2020. ↩︎ ↩︎
Passive immunotherapy for tauopathies: Current status and future directions. Nature Reviews Drug Discovery, 2021. ↩︎
Tau isoforms: Key players in neurodegeneration. Nature Reviews Neuroscience, 2021. ↩︎
Pinteon Therapeutics announces Phase 1 results for PNT001. ↩︎
Tau biomarkers in Alzheimer disease: Clinical applications. Nature Reviews Neurology, 2022. ↩︎
Tau pathology in traumatic brain injury: Mechanisms and therapeutic implications. Nature Reviews Neurology, 2020. ↩︎